The Alzheimer's drug lecanemab has been granted permission by the EU Commission for sale within the union as well as in Iceland, Liechtenstein, and Norway, announces the Swedish company Bioarctic in a press release.
The permission is given since EMA, the EU's pharmaceutical authority, approved lecanemab last winter. This after initially rejecting the medicine, which goes under the brand name Leqembi and was developed by Bioarctic together with the Japanese giant Eisai.
The drug is approved for the treatment of mild cognitive impairment and mild dementia due to Alzheimer's disease. It has already been approved in countries such as the USA, Japan, China, and the United Kingdom.
It is the first treatment that targets an underlying cause of Alzheimer's disease to be approved for sale by the EU.
